Definition
Lipodystrophy is referenced in the context of Tesamorelin, which is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. HIV-associated lipodystrophy involves abnormal redistribution of body fat and is the specific indication for which Tesamorelin has demonstrated significant visceral adipose tissue reduction in Phase III trials.
Source: Tesamorelin peptide summary and FAQ
Related Peptides